Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - rosiglitazone maleate 5.3mg equivalent to 4 mg rosiglitazone - film coated tablet - 4 mg - active: rosiglitazone maleate 5.3mg equivalent to 4 mg rosiglitazone excipient: hypromellose lactose monohydrate magnesium stearate opadry orange oy-l-23028 powdered cellulose sodium starch glycolate

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - rosiglitazone maleate 10.6mg equivalent to 8 mg rosiglitazone - film coated tablet - 8 mg - active: rosiglitazone maleate 10.6mg equivalent to 8 mg rosiglitazone excipient: hypromellose lactose monohydrate magnesium stearate opadry pink oy-l-24803 powdered cellulose sodium starch glycolate

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage);  ; ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage) - powder for injection - active: potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage)   ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage) - the treatment of infections caused by susceptible strains of organisms in the conditions listed below: - septicaemia (including bacteraemia) - lower respiratory tract infections - bone and joint infections - skin and skin structure infections - urinary tract infections - gynaecological infections - surgical prophylaxis appropriate culture and susceptibility tests should be performed in order to isolate and identify organisms causing infection and to determine their susceptibility to timentin. susceptibility to timentin will vary with geography and time and local succeptibility data should be consulted where available. in certain infections, when the causative organisms are unknown, timentin may be administered in conjunction with an aminoglycoside as initial therapy. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted as indicated. may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal hysterectomy, abdominal surgery, and colorectal surgery when there is a significant risk of postoperative infection or where occurrence of postoperative infection is considered to be especially serious.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - vi capsular polysaccharide of s. typhi ty2 25ug;   - solution for injection - 25 mcg/0.5ml - active: vi capsular polysaccharide of s. typhi ty2 25ug   excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate phenol sodium chloride water for injection - active immunisation against typhoid fever for adults and children older than two years of age.

Singapore - englanti - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - glyceryl trinitrate - tablet - 0.5 mg - glyceryl trinitrate 0.5 mg

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - mupirocin calcium -

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml;  ; potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml - powder for oral suspension - 125 mg/5ml - active: amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml   potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml;  ; potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml - powder for oral suspension - 250 mg/5ml - active: amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml   potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - mupirocin 2%{relative} ( + 10% overage ) - topical ointment - 2 % - active: mupirocin 2%{relative} ( + 10% overage ) excipient: macrogol 3350 macrogol 400 - latest regulatory activity

Singapore - englanti - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate eqv amoxycillin - capsule - 500 mg - amoxycillin trihydrate eqv amoxycillin 577.37 mg/capsule eqv 500mg amoxicillin